Condition: Mild, Moderate, or Severe Alzheimer's Disease · Sponsor: Elixiron Immunotherapeutics Inc.
An open-label, exploratory, phase II, proof-of concept, clinical study to assess the safety and tolerability of EI-1071 and the effects of EI-1071 on neuroinflammation in patients with mild, moderate, or severe Alzheimer's disease
This description comes directly from the study's public registry record.
Director Project Manager, Clinical Development · +886-2 2782 7700 · chi-yun.pai@elixiron.com
Always discuss trial participation with your own doctor first.
| Taipei Veterans General Hospital | Taipei, Taiwan | Recruiting |
| Tri-Service General Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06745583